Abstract: This system combines 3D printing technology with artificially modified cells for production of nonliving biomaterials. A 3D printer deposits a 3D array of bioengineered cells in the shape of a selected product. The cells are programmed to produce biomaterials in regulated amounts. The cell array deposits biomaterials onto a substrate. The cells and substrate are then removed, leaving a finished, nonliving product with microscale structure and precision.
July 15, 2015
Date of Patent:
October 27, 2020
United States of America as Represented by the Administrator of NASA
Diana M. Gentry, Christopher E. Venter, Lynn J. Rothschild
Abstract: The present invention relates to a cell culturing method and kit. More specifically, it relates to a cell culturing method and kit using a support that is exposed to the air. It further relates to a method of culturing cells by allowing them to migrate onto a porous polyimide film.
Abstract: Methods for reaction electrospinning are provided to form collagen fibers. The method can include: acidifying a collagen in an acidic solvent to form an acidic collagen solution; electrospinning the acidic collagen solution within an alkaline atmosphere (e.g., including ammonia vapor) to form collagen fibers; and collecting the collagen fibers within a salt bath (e.g., including ammonium sulfate). The acidic solvent can include water and an alcohol, and can have a pH of about 2 to about 4 (e.g., including a strong acid, such as HCl). An albumin rubber is also provided, which can include albumin crosslinked with glutaraldehyde.
September 28, 2015
Date of Patent:
August 4, 2020
University of South Carolina, MUSC Foundation for Research Development
Michael John Yost, Veronica Rodriguez-Rivera
Abstract: The present invention provides LIFR and FGFR3 as cell surface markers for isolating human cardiomyogenic ventricular progenitor cells, in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Thus, the invention provides human ventricular progenitor (HVP) cells. The invention provides in vitro methods of the separation of Islet 1+ LIFR+ ventricular progenitor cells and/or Islet 1+/FGFR3+ ventricular progenitor cells and/or Islet 1+/LIFR+/FGFR3+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated LIFR+ and/or FGFR3+ ventricular progenitor cells are also provided. Methods of in vivo use of LIFR+ and/or FGFR3+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the LIFR+ and/or FGFR3+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.
Abstract: The present invention provides Jagged 1 and Frizzled 4 as cell surface markers for isolating human cardiomyogenic ventricular progenitor cells, in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Thus, the invention provides human ventricular progenitor (HVP) cells. The invention provides in vitro methods of the separation of Islet 1+ Jagged 1+ ventricular progenitor cells and/or Islet 1+/Frizzled 4+ ventricular progenitor cells and/or Islet 1+/Jagged 1+/Frizzled 4+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated Jagged 1+ and/or Frizzled 4+ventricular progenitor cells are also provided. Methods of in vivo use of Jagged 1+ and/or Frizzled 4+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the Jagged 1+ and/or Frizzled 4+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.
Abstract: The present technology relates to foodstuffs that contain a substantially anhydrous fatty food that is solid at room temperature and comprises a substantially anhydrous probiotic bacterial preparation dispersed therein. Methods of making such substantially anhydrous fatty foods are also disclosed.
Abstract: A method of fabricating probiotics nanowhiskers using cheese comprises cutting and grinding cheese to produce cheese powder; mixing the cheese powder with sulfuric acid to produce a solution; stirring the solution to produce a stirred solution; and filtering the stirred solution to produce the probiotics nanowhiskers. The fabricated probiotics nanowhiskers possess antioxidant, anti-inflammatory, antitumor, and antimicrobial properties. The probiotics nanowhiskers may reduce cadmium concentration in a patient's liver. The probiotics nanowhiskers may also ameliorate the oxidative stress assessed as a decrease in the serum MDA levels in a patient.
September 11, 2018
Date of Patent:
December 31, 2019
King Saud University
Promy Virk, Manal Ahmed Gasmelseed Awad, Mai Abdelrahman Elobeid, Khalid Mustafa Osman Ortashi, Awatif Ahmed Hendi
Abstract: Method for the production of dextran comprising the following steps: prepare a culture medium containing the appropriated mixture and balance of ingredients, mainly after accurate selection of nature and concentration of carbon and nitrogen sources, with a specific initial pH, inoculate the culture medium with an appropriated quantity of bacteria strain (to standardize the production and avoid as much as possible the variability of the system); carry out the fermentation for a given time and at a given temperature; precipitate the dextran to separate the product from the culture medium; the bacteria strain is a strain of Weissella cibaria.
Abstract: The invention relates to a cheese includes angiogenin and/or angiogenin hydrolysate in an amount of 6.5 mg/100 g to 160 mg/100 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 33.
Abstract: This document provides methods and materials for treating a mammal (e.g., a human) having one or more stenotic blood vessels. For example, amnion coated balloons that can be used in balloon angioplasty are provided.
Abstract: A method of treating a cardio-renal disease is described that includes administering to a subject in need thereof a therapeutically effective amount of proprotein convertase subtilisin/kexin-6 (PCSK6), or an effective fragment thereof, which functions as a corin activator.
Abstract: Certain embodiments and aspects relate to a photobioreactor including encapsulating photobioreactor units (EPU) within which a liquid medium and a gas are encapsulated. The liquid medium comprises at least one species of phototrophic or mixotrophic organism therein. The gas comprises a high concentration of carbon dioxide. Certain methods of using the EPUs for algal biomass production use automated function units.
Abstract: The presently disclosed subject matter relates, in general, to the identification, isolation, and use of a population of stem cells isolated from umbilical cord blood, peripheral blood and/or other sources and that are referred to herein as Small Mobile Stem cells (short: SMS). More particularly, the presently disclosed subject matter relates to isolating said SMS stem cells and employing the same, optionally after in vitro manipulation, to treat tissue and/or organ damage in a subject in need thereof.
Abstract: To provide a microorganism culture vessel that can control existence of invading foreign matters and put a large amount of sample therein, a microorganism test kit, a method for testing a dialysate, a method for culturing the microorganism, a method for testing the microorganism and a method for producing the microorganism culture vessel. The invention includes the microorganism culture vessel, including an inlet-equipped culture bag in which a sheet-like medium is put and sealed.
Abstract: The invention provides a process for purifying lactoferrin from milk, the process comprising subjecting the milk to filtration to separate it into a retentate fraction comprising lactoferrin and a permeate fraction comprising growth factors and/or RNAses, wherein prior to and/or during filtration the milk is subjected to salt treatment such that growth factors and/or RNAses flow into the permeate. The invention also provides lactoferrin obtained from the process of the invention and uses thereof.
Abstract: The present invention provides a method for generating methane from a carbonaceous feedstock with simultaneous in situ sequestration of carbon dioxide to afford a biogas comprising at least 85 percent by volume methane, the method comprising anaerobically incubating a particulate additive in contact with a carbonaceous feedstock in a neutral or alkaline aqueous culture medium containing a culture of methanogenic consortia and collecting methane generated therefrom. The additive comprises at least one material selected from a biochar, an ash produced by gasification or combustion of a carbonaceous material, a black carbon soil, and a Terra Preta soil.
November 13, 2014
Date of Patent:
June 12, 2018
UCHICAGO ARGONNE, LLC
Seth W. Snyder, Meltem Urgun-Demirtas, Yanwen Shen
Abstract: The invention relates to a process for the production of alcohols from biomass that comprises a stage in which at least one aqueous internal flow that comprises at least one alcohol that has n carbon atoms, with n between 2 and 5, is recycled, provided that when the alcohol comprises 2 carbon atoms, it is mixed with at least one other alcohol in such a way as to recover a vapor phase effluent that contains alcohols exiting from said pretreatment reactor.
Abstract: A method for preparing a sterilized human acellular dermal allograft where the dermal allograft is sterilized by irradiation and has a greatly reduced bio-burden and enzymatic and antigenic activity. This product line of allografts can be easily used by surgeons in soft tissue replacement or repair and has an extended shelf life, of up to at least about three years.
Abstract: The present invention is directed towards methods for producing cell and tissue compositions suitable for therapeutic applications to a mammal in need of a therapeutic cell or tissue treatment. In particular, the invention is directed towards a method of culturing cells for use in therapy, which method comprises (i) culturing a sample of cells in a first cell culture medium and (ii) prior to harvesting cells for use in therapy culturing the cells in a second cell culture medium.